CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factorGuiqi Zhu, Ying–Hong Shi, Zheng Tang et al.|Cell Discovery|2023Cited by 329
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attackYuan Fang, Ying–Hong Shi, Weiren Liu et al.|Hepatology|2022Cited by 158
Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesisYufu Zhou, Ying–Hong Shi, Shushu Song et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 72
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantationWei‐Feng Qu, Ying–Hong Shi, Meng‐Xin Tian et al.|Hepatology International|2023Cited by 58
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world studyWei‐Feng Qu, Ying–Hong Shi, Guiqi Zhu et al.|BJS Open|2022Cited by 58